|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Laru-zova meets primary endpoint in pivotal VISTA trial for X-linked retinitis pigmentosa
2
The importance of treating EBMD before cataract surgery
3
How screen time and eyelid health affect dry eye risk
4
ESCRS 2026: Why surgeons should be willing to use what they prescribe to patients
5








